The drugmaker plans to transfer production from Hauppauge to its other facilities around the globe, including to a larger facility in South Yaphank, N.Y. However, some workers at the South Yaphank facility also will be laid off, according to the report.
The restructuring and layoffs are expected to save Amneal $50 million per year. The drugmaker will incur a one-time severance payment charge of $10 million to $12 million.
The drugmaker said it is losing money because of competition, sales declines and lower generic drug prices.
More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation’s 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.